Genzyme
Latest Genzyme News
-
Top 10 U.S. Cities for Super RichScientific, financial services company State Street Corp., medical device maker Boston Scientific and pharmaceutical company Genzyme . The cost of living is serious business in Boston, which has notoriously expensive houses in next-door Cambridge near
-
Fabry Disease Patients Get Sicker as Drugs Go Overseasanything." Since early August, Genzyme , the manufacturer of Fabrazyme one of 14 patients who are suing Genzyme for physical damages because of the Fabrazyme as Americans get sicker. Genzyme did not wish to comment on the lawsuit
-
Health Highlights: Nov. 16, 2009
FDA Warns of Steel Particles in Genzyme Drugs Doctors should watch out for rubber and fiber in five drugs made by Genzyme Corp., the U.S. Food and Drug Quality reports submitted by Genzyme alerted the FDA to the problem
-
Health Highlights: Nov. 13, 2009
FDA Warns of Steel Particles in Genzyme Drugs Doctors should watch out for rubber and fiber in five drugs made by Genzyme Corp., the U.S. Food and Drug Quality reports submitted by Genzyme alerted the FDA to the problem
-
New Drug Approved for Gaucher Disease
BioTherapeutics Inc. to give prGCD to patients in a clinical trial during a shortage of an older drug called Cerezyme, made by Genzyme Corp. That company had to discard most of its ingredients for Cerezyme after an FDA inspection of the manufacturing facility
-
Health Highlights: Aug. 17, 2009
BioTherapeutics Inc. to give prGCD to patients in a clinical trial during a shortage of an older drug called Cerezyme, made by Genzyme Corp. That company had to discard most of its ingredients for Cerezyme after an FDA inspection of the manufacturing facility
News
-
Some companies left behind in bull market's dust
companies, SP Acquisition Holdings, for roughly 52 cents a share. •Company-specific issues. Biotech company Genzyme genz is one of the larger firms to miss out on the rally, falling 10% to $49.36. It is working through production issues
-
Some companies left behind in bull's dust
companies, SP Acquisition Holdings, for roughly 52 cents a share. •Company-specific issues. Biotech company Genzyme genz is one of the larger firms to miss out on the rally, falling 10% to $49.36. It is working through production issues
-
Possible HRT Link to Lung Cancer Death
reported financial links with Amgen, AstraZeneca, Eli Lilly, Novartis and Wyeth. Johnson reported financial links with Genzyme , Boston Scientific, Celgene, and Johnson and Johnson.
-
Stem Cells Buy Freedom From Insulin for Type 1 Diabetics
partially. There were some side effects noted, but no deaths among the participant group. The study was funded in part by Genzyme Corp. and Johnson & Johnson-LifeScanBrazil. More information The American Diabetes Association has more on type 1 diabetes
-
Look for a list of industry leaders in 10-K reports
a number of biotechnology companies with resources far greater than ours may also emerge as competitors. These include Genzyme , Amgen, Cephalon, Shire Pharmaceuticals, BioMarin, Celgene, Biogen Idec, and Titan Pharmaceuticals/Schering AG
-
Businesses put politics aside, take new president in stride
Connie Mack, a former Republican senator from Florida who sits on the boards of four public companies — including Genzyme and Darden Restaurants, which operates Red Lobster and Olive Garden — says it makes sense that corporate boards would
-
Businesses put politics aside, take new president in stride
Connie Mack, a former Republican senator from Florida who sits on the boards of four public companies — including Genzyme and Darden Restaurants, which operates Red Lobster and Olive Garden — says it makes sense that corporate boards would
Videos
-
Markets Watch New Economic IndicatorsBiotech firms will percent of buying Genzyme and the price tag twenty billion months this deal has been in the works Genzyme shareholders of them 74 dollars in cash and also other incentives. Now Genzyme that's the world's largest maker
huge merger between two European Biotech firms will percent of -- buying Genzyme and the price tag twenty billion dollars and his -- a -- time coming. -- nine months this deal has been in the works Genzyme shareholders of them -- 74 dollars in cash and also other incentives. Now Genzyme that's the world's largest maker of medicines for rare genetic disorders and this is going to help -- -- deal with. All -- increasing competition from the generics out there and analysts saying. That this steel bikes and a little more time for those generics now the problem is for a lot of these companies. It's when your top sellers and up going -- -- now Genzyme on the other hand they've been independent for about thirty years. But manufacturing glitches that led to shortages of their drugs back
